Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie - 1 Feb 2024

Jung Ronja, Kempf Melanie, Holocher Saskia, Kortüm Friederike C, Stingl Krunoslav, Stingl Katarina

Abstract excerpt

BACKGROUND: Voretigene neparvovec (Luxturna®) is the first approved gene therapy for RPE65-linked Leber congenital amaurosis (LCA). Though individual effects are highly variable, most recipients report improved vision in everyday life. To describe such effects, visual navigation tests are now frequently used in clinical trials. However, it is still unclear how their results should be interpreted compared to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to cis-trans-Isomerases
Share to Genetic Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leber Congenital Amaurosis

Share to Mutation

Share to Retina

Share to Vision, Ocular

Share to Visual Acuity

Source

Open in PubMed Open full text

Identifiers

PMID: 37768368
DOI: 10.1007/s00417-023-06237-4
PMCID: PMC10844143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multi-luminance mobility testing after gene therapy in the context of retinal functional diagnostics.PMID 37768368Read ↗

Mobility test to assess functional vision in dark-adapted patients with Leber congenital amaurosis.Semantic proximity Read ↗

Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical EvidenceSemantic proximity Read ↗

Voretigene neparvovec-rzyl for treatment of RPE65-mediated inherited retinal diseases: a model for ocular gene therapy developmentSemantic proximity Read ↗

Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.Semantic proximity Read ↗

Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.Semantic proximity Read ↗

Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.Semantic proximity Read ↗

Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.Semantic proximity Read ↗

Gene therapy outcomes in young patients with RPE65-retinal degeneration.Semantic proximity Read ↗

Full-field stimulus testing: Role in the clinic and as an outcome measure in clinical trials of severe childhood retinal disease.Semantic proximity Read ↗

The first gene therapy for RPE65 biallelic dystrophy with voretigene neparvovec-rzyl in Brazil.Semantic proximity Read ↗

Defining the residual vision in leber congenital amaurosis caused by RPE65 mutations.Semantic proximity Read ↗

Improvement and decline in vision with gene therapy in childhood blindness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.